Skip to content

OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Share this press release:

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use